|
Abnormal behavior
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Neurofilaments are cytoskeletal proteins in the neurons, and several studies have reported elevated levels of neurofilament light chain (NfL) in cerebrospinal fluid of neurodegenerative as well as psychiatric disorders.
|
30953863 |
2019 |
|
Abnormal behavior
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
This study explored the utility of cerebrospinal fluid neurofilament light in distinguishing primary psychiatric disorders from neurodegenerative and neurological disorders, a common diagnostic dilemma for psychiatrists and neurologists.
|
31220922 |
2020 |
|
Abnormal behavior
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders.
|
31595378 |
2020 |
|
Absent reflex
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Adult Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Either suppressing miR-381 or enforcing NEFL expression dramatically sensitized glioblastoma cells to temozolomide (TMZ), a promising chemotherapeutic agent for treating GBMs.
|
25605243 |
2015 |
|
Adult Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-binding site located on the light neurofilament subunit, selectively enters in glioblastoma cells where it disrupts their microtubule network and inhibits their proliferation.
|
23152907 |
2012 |
|
Adult Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results indicate that the NFL-TBS.40-63 peptide represents a promising therapeutic drug for glioblastoma treatment by targeting and killing both glioblastoma cells and BTICs to prevent recurrence.
|
31132447 |
2019 |
|
Adult Myxopapillary Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The upregulation of three genes of interest, homeobox B13 (HOXB13), neurofilament, light polypeptide (NEFL) and PDGFR alpha, was further studied by immunohistochemistry in a larger cohort that included adult MEPN and EPN specimens.
|
19793339 |
2010 |
|
Adult Subependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunoreactivity for HOXB13, NEFL and PDGFR alpha was strongest in MEPN and virtually absent in subependymoma.
|
19793339 |
2010 |
|
Agenesis of corpus callosum
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The recognized CMT2 genotypes include: CMT2A (mapped to chromosome 1p35-36); CMT2B (3q13-22); CMT2C (with vocal cord paresis); CMT2D (7p14); CMT2E, related to a mutation in the NF-L gene on chromosome 8p21; proximal CMT2, or HMSN P (3q13.1); CMT2 with MPZ mutations; autosomal recessive CMT2 (1q21.2-q21.3); agenesis of the corpus callosum with sensorimotor neuronopathy (15q13-q15); CMT2 X-linked with deafness and mental retardation (Xq24-q26).
|
11231025 |
2001 |
|
Agenesis of corpus callosum
|
0.020 |
Biomarker
|
disease |
BEFREE |
Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).
|
26556829 |
2016 |
|
AIDS Dementia Complex
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.
|
17492593 |
2007 |
|
Alzheimer disease, familial, type 3
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Messenger RNA (mRNA) transcripts [amyloid precursor protein (APP), α-synuclein (α-syn), Tau, neurofilament light gene (NF-L), DJ-1/PARK7, Fractalkine and Neurosin] and long non-coding RNAs (RP11-462G22.1 and PCA3) were differentially expressed in CSF exosomes in PD and AD patients.
|
26497684 |
2015 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (Aβ<sub>1-42</sub>, t-tau, p-tau<sub>181</sub>, NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 ± 10.4, 70.4 ± 7.7, 71.7 ± 8.4, 76.2 ± 3.5 years [mean ± SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters.
|
31585366 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients.
|
30951523 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlation coefficients between NFL levels and important AD indices reported by individual studies were pooled as z-scores.
|
31572170 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration.
|
29070659 |
2017 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cerebrospinal fluid NFL levels were quantified in nonprimarily neurodegenerative neurological and psychiatric diseases (n = 122), mild cognitive impairment (n = 48), Alzheimer's disease (n = 108), dementia with Lewy bodies/Parkinson's disease dementia (n = 53), vascular dementia (n = 46), frontotemporal dementia (n = 41), sporadic Creutzfeldt-Jakob disease (sCJD, n = 132), and genetic prion diseases (n = 182).
|
29391125 |
2018 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subjects with APOE ε4 have higher CSF NFL levels than non-ε4 carriers, only when they do not carry a short poly-T variant of TOMM40, which is associated with later age of onset of AD, and may act as protective against the dose effect of ε4.
|
21983493 |
2012 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
|
31601232 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
No differences in accessibility to the nuclease probe was found between AD-affected and control temporal grey matter nuclei for the human prion HuPrP gene or for the NF-L gene in nuclei isolated from the primary visual cortex or the cerebellum.
|
2159582 |
1990 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals.
|
31673598 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether baseline concentrations of plasma total tau (t-tau) and neurofilament light (NfL) chain proteins are associated with annual percent change (APC) of the basal forebrain cholinergic system (BFCS) in cognitively intact older adults at risk for Alzheimer disease (AD).
|
31801830 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) from 51 AD subjects who participated in the randomized controlled trial Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise (ADEX) was analyzed for the concentration of neurofilament light (NFL), neurogranin (Ng), visinin-like protein-1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40).
|
29067334 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurofilament light (NF-L) is a surrogate marker in plasma and cerebrospinal fluid (CSF) for neurodegeneration (Abu-Rumeileh et al., Alzheimers Res Ther 10: 3, 2018; Mattsson et al., JAMA Neurol 74: 557-566, 2017) but continues to be a controversial biomarker for both HAND and AD (Gisslen et al., EBioMedicine 3: 135-140, 2016; Kovacs et al., Eur J Neurol 24:1326-e77, 2017; Norgren et al., Brain Res 987: 25-31, 2003; Rolstad et al., J Alzheimers Dis 45: 873-881, 2015; Yilmaz et al., Expert Rev Mol Diagn 17: 761-770, 2017).
|
30610738 |
2019 |